Novo Nordisk A/S is undercutting arch-rival Eli Lilly & Co. on obesity drugs for cash-pay patients, showing its willingness to compete on price as it tries to claw back a larger share of the US market.
www.bloomberg.com
#Novo #Undercuts #Lillys #Obesity #Drug #Price #CashPay #Patients
Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.…
LifeScan Global Corp., the glucose-monitor maker backed by private equity firm Platinum Equity, filed for a prearranged bankruptcy protection in…
Representative Suhas Subramanyam, a Virginia Democrat, joined Balance of Power stating that President Trump’s “outrageous” threats to hit civilian targets…
